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ABSTRACT: Lacosamide ((R)-1) is a recently marketed,
first-in-class, antiepileptic drug. Patch-clamp electrophysiology
studies are consistent with the notion that (R)-1 modulates
voltage-gated Na+ channel function by increasing and
stabilizing the slow inactivation state without affecting fast
inactivation. The molecular pathway(s) that regulate slow
inactivation are poorly understood. Affinity baits are chemical
reactive units, which when appended to a ligand (drug) can
lead to irreversible, covalent modification of the receptor thus
permitting drug binding site identification including, possibly,
the site of ligand function. We describe, herein, the synthesis of
four (R)-1 affinity baits, (R)-N-(4″-isothiocyanatobiphenyl-4′-
yl)methyl 2-acetamido-3-methoxypropionamide ((R)-8), (S)-N-(4″-isothiocyanatobiphenyl-4′-yl)methyl 2-acetamido-3-methox-
ypropionamide ((S)-8), (R)-N-(3″-isothiocyanatobiphenyl-4′-yl)methyl 2-acetamido-3-methoxypropionamide ((R)-9), and (R)-
N-(3″-acrylamidobiphenyl-4′-yl)methyl 2-acetamido-3-methoxypropionamide ((R)-10). The affinity bait compounds were
designed to interact with the receptor(s) responsible for (R)-1-mediated slow inactivation. We show that (R)-8 and (R)-9 are
potent inhibitors of Na+ channel function and function by a pathway similar to that observed for (R)-1. We further demonstrate
that (R)-8 function is stereospecific. The calculated IC50 values determined for Na
+ channel slow inactivation for (R)-1, (R)-8,
and (R)-9 were 85.1, 0.1, and 0.2 μM, respectively. Incubating (R)-9 with the neuronal-like CAD cells led to appreciable levels of
Na+ channel slow inactivation after cellular wash, and the level of slow inactivation only modestly decreased with further
incubation and washing. Collectively, these findings have identified a promising structural template to investigate the voltage-
gated Na+ channel slow inactivation process.
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Lacosamide1 ((R)-1) is a first-in-class antiepileptic drug(AED) that has been marketed for adjuvant treatment of
partial-onset seizures in adults.2 Whole animal pharmacological
studies showed that the (R)-1 anticonvulsant profile is unique
and prevents seizure spread by mechanisms different from
other AEDs.3 Radioligand displacement assays using more than
100 potential receptors did not reveal high-affinity binding
targets.4 These findings suggested that (R)-1 function is unique
or that binding is weak or both. Recent patch-clamp
electrophysiology studies demonstrated that (R)-1 modulated
voltage-gated Na+ channel (VGSC) function by likely
increasing and stabilizing the slow inactivation process without
affecting fast inactivation.5−8 The experimental findings were
also consistent with a mechanism in which (R)-1 blocks fast
inactivated channels with very slow kinetics.5,6 No other
anticonvulsant is reported to preferentially modulate Na+
channel slow inactivation. The molecular pathway for this
interaction has not been determined; thus, it is not known
whether (R)-1 exerts its activity by directly interacting with the
Na+ channel or through an intermediary protein.
Affinity baits are chemical reactive units that lead to
irreversible, covalent modification of the receptor when they
are appended to a ligand (drug) (Figure 1, 2 + 3 ⇌ 4 →
5).9−21 This technology has been used to identify binding
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partners and their approximate binding location when ligand
binding is modest. Different electrophilic and photoactivable
affinity bait units have been advanced.9−14 Among the
electrophilic affinity baits are isothiocyanate and acrylamide
groups.14−16,20−30 Isothiocyanates and acrylamides display an
excellent balance between stability and reactivity; they do not
readily react with hydroxylic solvents (thus permitting their
dissolution in aqueous solutions) but do react with biological
nucleophiles (e.g., thiols, amines) with minimal nonspecific
background labeling of cellular constituents.9,28−30
We have shown that the lacosamide 4′-isothiocyanate affinity
bait agent (R)-6 given orally to rats exhibited anticonvulsant
activity comparable to (R)-1 in the maximal electroshock
seizure (MES) test31 (ED50 (mg/kg): (R)-1, 3.9; (R)-6, 4.2).
32
We also demonstrated that (R)-6, like (R)-1, likely promoted
Na+ channel slow inactivation in catecholamine A differentiated
(CAD) cells (IC50 (μM): (R)-1, 85; (R)-6, 8.1).
7 Finally, we
found that (R)-6 increased this Na+ channel inactivation far
more effectively than (S)-6 (IC50 (μM): (R)-6, 8.1; (S)-6, 68),
a finding consistent with their activities in the MES test in rats
(ED50 (mg/kg): (R)-6, 4.2; (S)-6, >180).
32 When we incubated
(R)-6 (five times the calculated slow inactivation IC50 value)
with CAD cells (37 °C, 10 min), it retained only a modest
increase (∼10%) in the levels of inactivation after (R)-6 was
removed from the reaction solution (cellular wash), indicating a
low efficiency of covalent adduction by the affinity bait
reagent.7 Recently, we reported that the N-(biphenyl-4′-
yl)methyl amide derivative (R)-7,33 which differed from (R)-1
by an incorporated 4′-aryl unit (see box in (R)-7), had greater
Na+ channel inactivation in CAD cells than (R)-1 (calculated
slow inactivation IC50 (μM): (R)-1, 85; (R)-7, 2.9).
34 This
finding suggested that lacosamide-like affinity bait compounds
containing a N-(biphenyl-4′-yl)methyl amide unit would lead
to a comparable increase in slow inactivation, and with CAD
cell incubation an increased percentage of the Na+ channels
irreversibly converted to the slow-inactivated state.
Here we report the synthesis of a series of (R)-1 affinity bait
agents ((R)-8−(R)-10) designed to interact with the
receptor(s) responsible for (R)-1-mediated slow inactivation.
We show that the isothiocyanate analogues (R)-8 and (R)-9
potently modulated Na+ channel inactivation similar to (R)-1
and that (R)-8 function was stereospecific. We further show
that (R)-9 incubation with CAD cells led to appreciable levels
of inactivated Na+ channels consistent with slow inactivation
after cellular wash and that the extent of slow inactivation only
modestly decreased with further heating and cellular wash. The
implications of these findings are discussed.
■ RESULTS
Chemistry. Affinity bait agents (R)-8, (S)-8, (R)-9, and (R)-
10 were prepared using a similar route to the one used to
construct 4′-substitued (R)-1 analogues35 (Scheme 1).
Optically pure 2-acetamido-3-methoxypropionic acid35 (16)
was coupled through its mixed anhydride36 with either (4″-N-
(tert-butoxycarbonyl)aminobiphenyl-4′-yl)methylamine (14) or
(3″-N-(tert-butoxycarbonyl)aminobiphenyl-4′-yl)methylamine
(15) without racemization to give 17 and 18. Amines 14 and
15 were prepared by Suzuki coupling37 (Pd(PPh3)4, K2CO3) of
Figure 1. Affinity bait (AB) and strategy for target receptor modification. Proposed pathway for receptor modification by a ligand that binds with
modest affinity to its cognate receptor. Ligand 2 reversibly binds to receptor 3 to provide complex 4. Modification of the receptor by 2 proceeds
through the affinity bait (AB) to give covalent ligand−receptor adduct 5.
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4-bromobenzylamine (11) and either 4-(12) or 3-(13) (N-tert-
butoxycarbonylamino)phenylboronic acid. HCl deprotection of
17 and 18 gave the corresponding arylamines 19 and 20,
respectively, after basification, which was converted to the
affinity bait agents (R)-8, (S)-8, and (R)-9 using di(2-pyridyl)
thionocarbonate (DPT). Reaction of (R)-20 with acryloyl
chloride and triethylamine gave acrylamide (R)-10. We
confirmed the optical purity of (R)-8, (S)-8, (R)-9, and (R)-
10 by 1H NMR using the chiral resolving agent (R)-
(−)-mandelic acid.38
Pharmacology. Inhibition of Na+ Currents by (R)-8, (S)-8,
(R)-9, and (R)-10. Using the whole-cell patch-clamp config-
uration, we examined the effects of the affinity bait compounds
on voltage-gated Na+ channels in CAD cells. We previously
reported that CAD cells express endogenous tetrodotoxin-
sensitive Na+ currents with rapid activation and inactivation
kinetics upon membrane depolarization and are likely
composed of Na+ channel isoforms NaV1.7, NaV1.1, and
NaV1.3.
7,39,40 Our results have demonstrated that the Na+
channel properties of (R)-1 in CAD cells7 were similar to
those reported in neurons in culture and in mouse N1E-115
neuroblastoma cells.5 Accordingly, we used readily accessible
CAD cells to evaluate the effects of the affinity bait compounds
on Na+ channel function, recognizing in advance that CAD cells
do not express the same set of Na+ channels expressed in CNS
neurons. First, we tested the ability of the affinity bait agents to
inhibit peak inward Na+ currents by holding CAD cells at −80
mV and executing a current (I)−voltage (V) protocol, which
consisted of 15-ms-step depolarizations ranging from −70 to
+80 mV (in +10 mV increments; Figure 2A). An exemplar
trace of the peak currents from untreated cells and those
treated with 1 μM of (R)-8 and (R)-9 are illustrated in Figure
2B. Compared to control currents (peak current value of
−124.9 ± 10.5 pA/pF at +0 mV for untreated cells (n = 9)),
peak macroscopic Na+ currents were inhibited by 60−70% for
(R)-8, (S)-8, and (R)-9 and ∼16% for (R)-10 (Figure 2). The
inhibition of Na+ currents was not accompanied by changes in
reversal potential for any of the affinity bait compounds (data
not shown).
As changes in current inhibition could be due to changes in
channel gating properties, we tested if the affinity bait
compounds altered the voltage-dependence of activation of
Na+ currents in CAD cells. Changes in activation for the CAD
cells treated with the affinity bait compounds were measured by
whole-cell ionic conductances by comparing their respective
midpoints (V1/2) and slope factors (k) in response to changes
in command voltage (Figure 3, right curves). The calculated
V1/2 and k values (Table 1) showed that activation V1/2 was
shifted by 3.1 and 5.9 mV in the depolarizing direction by (R)-8
and (S)-8, respectively, and by 7.9 and 1.7 mV in the
hyperpolarizing direction by (R)-9 and (R)-10, respecively.
There were no appreciable shifts in slope values compared to
control except for a slight increase in slope with 100 nM of (R)-
9. Thus, these results suggest that (R)-8, (S)-8, and (R)-9, but
not (R)-10, are effective inhibitors of peak Na+ currents, and
that maximal inhibition is observed for affinity bait compounds
possessing the (R)-configuration.
Scheme 1. Synthesis of Affinity Compounds
Figure 2. Inhibition of macroscopic Na+ currents by affinity bait
derivatives of lacosamide. (A) Voltage protocol used to elicit
macroscopic Na+ currents in CAD cells. (B) Representative current
responses, at a step voltage to 0 mV, of CAD treated with 0.1% DMSO
control, 1 μM (R)-8, and 1 μM (R)-9. (C) Summary of peak current−
voltage (I−V) relationships for CAD cells treated with 0.1% DMSO
(control) or varying concentrations of (R)-8 (n = 4−8). Current
responses were evoked by a step from a holding potential of −80 mV
and stepping up in 10 mV increments from −70 to +60 mV. (D)
Percent inhibition of peak current density (pA/pF), at 0 mV, from
CAD cells treated with 1 μM of (R)-8, (S)-8, (R)-9, and (R)-10.
Inhibition was determined by normalizing peak currents in each drug
condition to average peak currents obtained in DMSO-treated cells.
Asterisks indicate statistically significant differences in peak inhibition
between predrug (control) and the indicated concentrations of (R)-
and (S)-compounds (p < 0. 05, ANOVA with posthoc Dunnett’s test).
Numbers in parentheses are the number of cells patched per condition.
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Fast Inactivation Properties of Na+ Currents in CAD Cells
Are Not Affected by (R)-8, (S)-8, (R)-9, and (R)-10. Since our
data were consistent that most of the lacosamide-like affinity
bait agents exhibited profound effects on Na+ channels slow-
inactivated state (see Figures 4−7), we determined if these
compounds could alter steady-state fast inactivation using a
previously described protocol designed to induce a fast-
inactivated state.7,39 Cells were held at −80 mV, stepped to
inactivating prepulse potentials ranging from −120 to −10 mV
(in 10 mV increments) for 500 ms, then the cells were stepped
to 0 mV for 20 ms to measure the available current (Figure 3,
top left protocol). A 500 ms conditioning pulse was used
because it allowed all of the endogenous channels to transition
to a fast-inactivated state at all potentials examined. Steady-
state, fast inactivation curves of Na+ currents from DMSO-,
(R)-8-, (S)-8-, (R)-9-, and (R)-10-treated CAD cells were well
fitted with a single Boltzmann function (R2 > 0.967 for all
conditions). The Boltzmann curves for (R)-8-treated cells are
illustrated in Figure 3 (leftmost curves). The V1/2 value for
inactivation for 0.1% DMSO-treated cells was −68.4 ± 3.1 mV
(n = 9), which was not significantly different from the V1/2
values of most concentrations of (R)-8-, (S)-8-, (R)-9-, or (R)-
10- treated cells (Table 2; p > 0.05; ANOVA with a posthoc
Dunnett’s test). The 100 nM concentration of (R)-9 caused a
significant hyperpolarizing shift of ∼14 mV (Table 1) with no
commensurate change in slope compared to control cells. The
slopes of fast inactivation were not affected by the affinity bait
agents. Similar results were observed for (R)-1 and (R)-6.7
(R)-8, (S)-8, (R)-9, and (R)-10 Affect the Transition to a
Slow-Inactivated State of Na+ Currents in CAD Cells. Recent
studies indicate that (R)-1 reduces VGSC availability by
selectively increasing VGSCs’ transition to a slow-inactivated
state.5−8,39 We recognize that the observed data is also
consistent with a mechanism where (R)-1 blocks Na+ fast
inactivated channels with very slow kinetics.41 Like earlier
researchers, we have assumed that (R)-1-induced Na+ channel
modulation proceeds by the slow inactivation pathway.
Accordingly, we used protocols similar to those employed for
(R)-15−8 and tested the ability of the affinity bait agents to
modulate transition to the slow-inactivated state in CAD cells.
CAD cells were held at −80 mV and conditioned to potentials
ranging from −120 to +20 mV (in +10 mV increments) for 5 s.
Then, fast-inactivated channels were allowed to recover for 150
ms at a hyperpolarized pulse to −120 mV, and the fraction of
channels available was tested by a single depolarizing pulse, to 0
mV, for 15 ms (Figure 4A). This brief hyperpolarization
allowed the channels to recover from fast inactivation while
limiting recovery from slow inactivation.
A representative family of slow inactivation traces from CAD
cells treated with 1 μM (R)-9 is shown in Figure 4B. For
comparison, representative current traces at −50 mV are
highlighted. As reported earlier,7,39 this potential was selected
for three reasons: (1) most channels are undergoing steady-
state inactivation, likely involving contributions from slow- and
fast-inactivating pathways42,43 where −50 mV is in the steep
voltage-dependence range for each; (2) it approximates the
resting membrane potential and approaches the action potential
firing threshold of CNS neurons,44 where slow inactivation
appears to be physiologically important during sustained
subthreshold depolarizations;45 and (3) changes in the Na+
channel availability near −50 mV can impact the window
Figure 3. Effects of isothiocyanate compound (R)-8 on activation and
inactivation properties of Na+ currents in CAD cells. Values for V1/2,
the voltage of half-maximal activation and steady-state fast inactivation
and the slope factors (k) were derived from Boltzmann distribution fits
to the individual recordings and averaged to determine the mean
(±SEM) voltage dependence of activation and fast inactivation. The
voltage protocol used to evoke current responses for each protocol is
shown above the fits. Representative Boltzmann fits for activation and
steady-state inactivation for CAD cells treated with 0.1% DMSO
(control) and indicated concentrations of (R)-8 are shown. The
calculated values for V1/2 and k of activation and steady-state
inactivation for all concentrations of the four affinity bait compounds
tested in this study are presented in Tables 1 and 2, respectively.
Table 1. Comparative Boltzmann Parameters of Voltage-
Dependence of Channel Activation Curves for the
Respective Affinity Bait Reagentsa
condition concentration V1/2 k
control −12.8 ± 0.5 (4) 7.4 ± 0.5 (4)
(R)-8 30 nM −12.3 ± 0.8 (5) 6.6 ± 0.7 (5)
100 nM −12.9 ± 0.3 (5) 6.7 ± 0.3 (5)
300 nM −9.7 ± 0.7 (4) 7.3 ± 0.6 (4)
1 μM −11.3 ± 0.5 (5) 7.5 ± 0.4 (5)
3 μM −12.2 ± 0.5 (6) 7.1 ± 0.5 (6)
(S)-8 300 nM −10.8 ± 0.4 (4) 6.9 ± 0.4 (4)
1 μM −6.9 ± 0.4 (5)* 7.1 ± 0.3 (5)
3 μM −9.1 ± 0.6 (5) 6.4 ± 0.5 (5)
10 μM −9.3 ± 0.4 (4) 7.1 ± 0.3 (4)
30 μM −13.7 ± 0.6 (5) 6.8 ± 0.5 (5)
(R)-9 300 pM −16.9 ± 1.0 (4) 6.2 ± 0.7 (4)
1 nM −20.8 ± 2.0 (4)* 8.4 ± 1.5 (4)
100 nM −12.6 ± 1.8 (4) 10.0 ± 1.3 (4)
1 μM −15.0 ± 0.6 (2) 6.2 ± 0.6 (2)
(R)-10 3 μM −13.0 ± 0.5 (4) 6.8 ± 0.4 (4)
30 μM −14.5 ± 1.0 (5) 6.3 ± 0.5 (5)
100 μM −13.9 ± 1.4 (5) 6.8 ± 1.1 (5)
300 μM −13.8 ± 1.7 (4) 6.9 ± 1.0 (4)
aValues for V1/2, the half-maximal activation, and the slope factors (k)
were derived from Boltzmann distribution fits to the individual
recordings and averaged to determine the mean and standard error (±
SEM) displayed above. Asterisk (∗) indicates statistical significance (p
< 0.05) compared to control values (one-way ANOVA with Tukey’s
posthoc test).
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current of Na+ current activation and inactivation under steady-
state conditions.43,46 Compared with control (untreated cells),
adding (R)-8 to CAD cells induced a greater decrease in the
fraction of current available than (S)-8. When we added 1 μM
(R)-8 to CAD cells, we found that, at −50 mV, 0.39 ± 0.01
fractional units (n = 5) of the Na+ current were available
compared with DMSO-treated cells after a 10 min incubation
period, suggesting that in these cells a large fraction (0.61 ±
0.01; calculated as 1 minus the normalized INa) of the channels
transitioned to a nonconducting (slow-inactivated) state
(Figure 4C). Correspondingly, in the 30 μM (S)-8-treated
cells, the slow-inactivated fraction was 0.29 ± 0.05 (Figure 4D).
A similar enantioselective increase of slow inactivation was
observed for 1 and 6.7 When we treated CAD cells with either
(R)-9 (1 μM) or (R)-10 (1 μM), substantial levels of slow
inactivation were observed at −50 mV for only (R)-9 (fraction
of the channels to transition to a nonconducting (slow-
inactivated) state: (R)-9, 0.62 ± 0.03 (n = 4); (R)-10, 0.20 ±
0.04 (n = 5)) (Figure 4E, F).
To further understand the extent to which the four affinity
bait compounds induced slow inactivation, we determined the
concentration response curves for slow inactivation induction
for each compound (Figure 4C−F). Using the Boltzmann
equation, we fit the voltage dependence of slow inactivation for
the control and for each of the drug concentrations. This
yielded a V1/2 value of slow inactivation for each concentration,
which was then plotted against the concentration used. Finally,
fits of the concentration response of slow inactivation against
the V1/2 of slow inactivation provided an IC50 value. This value
is likely a reflection of presumptive drug binding and bonding
to a slow inactivation site on the Na+ channels. Compared with
our recently reported IC50 values of 85 and 8.1 μM for slow
Figure 4. Affinity bait compounds affect steady-state slow inactivation state of Na+ currents in CAD cells. (A) Voltage protocol utilized to isolate the
slow inactivated fraction of currents. Currents were evoked by 5 s prepulses between −120 and −20 mV, and then fast-inactivated channels were
allowed to recover for 150 ms at a hyperpolarized pulse to −120 mV. The fraction of channels available at 0 mV was then analyzed. (B)
Representative family of current traces from CAD cells in the presence of DMSO (control) or 1 μM (R)-9. The dashed black (control) and solid
blue traces ((R)-9) in the current recordings depict the current at −50 mV (also highlighted by dashes in the voltage protocol). (C−F) Summary of
steady-state, slow-activation curves for CAD cells treated with (R)-8 (C), (S)-8 (D), (R)-9 (E), and (R)-10 (F). Drug-induced slow inactivation was
more prominent in CAD cells treated with (R)-8 and (R)-9 than (S)-8 or (R)-10 at almost all concentrations tested.
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inactivation by (R)-1 and (R)-6, respectively,7 the IC50 values
for the (R)-8, (S)-8, (R)-9, and (R)-10 were 100.1 nM ± 3.8
(R2 = 0.988), 1.1 ± 0.2 μM (R2 = 0.994), 202.8 nM ± 8.9 (R2 =
0.979), and 401.0 ± 9.8 μM (R2 = 0.987), respectively. The
enantioselective effect observed for 8 (IC50 (S)-8/IC50 (R)-8:
11.0) mirrored that found for 6 (IC50 (S)-6/IC50 (R)-6: 8.4).
7
These data are consistent with the notion that (R)-8 and (R)-9
effectively increased the transition of Na+ channels to a slow-
inactivated state. We showed that for 8 this activity
preferentially resided in the (R)-stereoisomer. Moreover, we
demonstrated that adding the aryl group to (R)-6 to give (R)-8
led to an ∼80-fold decrease (increased potency) in the CAD
cell IC50 value for slow inactivation induction. Similarly, for
(R)-9, a positional isomer of (R)-8, we observed a ∼40-fold
decrease in the IC50 value versus (R)-6.
Extent of Slow Inactivation by (R)-8 and (R)-9 due to
Covalent Modification. The enhanced potency of (R)-8 and
(R)-9 compared with (R)-6 in increasing slow inactivation may
represent the combined effects of the affinity bait agent binding
to the receptor(s) (Figure 1, 4) and the subsequent covalent
adduction of the affinity bait agent (Figure 1, 5). Thus, we
asked if the observed increase in slow inactivation was due, in
part, to the formation of stable, covalent adduct(s). If the
affinity bait agent irreversibly affects Na+ channel slow
inactivation by covalently modifying a receptor, then slow
inactivation may still be observed when the drug derivative is
removed from the CAD cells by extensive washing with an
extracellular bath solution. Alternatively, if the affinity bait agent
increases Na+ channel slow inactivation by a reversible process,
then when the agent is removed from the test reaction recovery
from slow inactivation should be observed.
To distinguish between these possibilities, we treated CAD
cells with either (R)-1, (R)-8, or (R)-9 at five times their
calculated slow inactivation IC50 values for 10 min, which is
expected to inhibit >99% of the slow inactivation, extensively
washed the cells (three times) over a 10 min period, and then
the level of slow inactivation was determined (Figure 5A). We
found that the extent of Na+ channel slow inactivation for the
CAD cells treated with either (R)-1 or (R)-8 after washing was
nearly the same as that of untreated cells, while cells treated
with (R)-9 and then washed still retained 19% of the Na+
channels in the slow inactivated state (Figure 5B). The
comparable levels of slow inactivation for the (R)-1-treated,
(R)-8-treated, and untreated cells after cellular wash indicated
that the wash conditions were sufficient to remove the affinity
bait agents from the test solution and resulted in no loss of
channel function. The level of Na+ channel slow inactivation for
Table 2. Comparative Boltzmann Parameters of Voltage-
Dependence of Channel Steady-State Fast Inactivation
Curves for the Respective Affinity Bait Reagentsa
condition concentration V1/2 k
control −68.4 ± 3.1 (5) 4.6 ± 1.6 (5)
(R)-8 30 nM −66.5 ± 1.2 (5) 4.4 ± 0.4 (5)
100 nM −67.6 ± 2.1 (5) 4.9 ± 0.3 (5)
300 nM −66.6 ± 0.8 (5) 5.4 ± 0.5 (4)
1 μM −70.8 ± 1.2 (5) 5.0 ± 0.3 (5)
3 μM −67.8 ± 0.6 (6) 5.1 ± 0.5 (6)
(S)-8 300 nM −68.8 ± 0.3 (4) 4.9 ± 0.3 (4)
1 μM −64.2 ± 0.3 (5) 4.8 ± 0.3 (5)
3 μM −65.0 ± 0.3 (5) 4.9 ± 0.2 (5)
10 μM −73.0 ± 0.5 (4) 5.7 ± 0.4 (4)
30 μM −70.7 ± 0.3 (5) 5.1 ± 0.3 (5)
(R)-9 300 pM −78.6 ± 1.3 (4)* 5.4 ± 0.6 (4)
1 nM −76.8 ± 1.3 (4) 5.1 ± 0.6 (4)
100 nM −82.4 ± 2.3 (4)* 6.9 ± 0.9 (4)
1 μM −75.9 ± 2.9 (3) 4.2 ± 0.9 (3)
(R)-10 3 μM −70.4 ± 0.7 (5) 6.1 ± 0.7 (5)
30 μM −69.6 ± 0.7 (5) 4.2 ± 0.6 (5)
100 μM −69.7 ± 4.2 (5) 3.1 ± 4.2 (5)
300 μM −73.7 ± 1.0 (4) 5.5 ± 0.6 (4)
aValues for V1/2, the half-maximal fast inactivation, and the slope
factors (k) were derived from Boltzmann distribution fits to the
individual recordings and averaged to determine the mean and
standard error (± SEM) displayed above. Asterisk (∗) indicates
statistical significance (p < 0.05) compared to control values (one-way
ANOVA with Tukey’s posthoc test).
Figure 5. Effect of (R)-8 and (R)-9 on Na+ currents slow inactivation (SI) and fast inactivation (FI). (A) Experimental design for the washout
experiments. For this and subsequent figures, the experiments were conducted on separate sets of cells in parallel with SI and FI assessments
performed at the times indicated by the arrows. Drugs were not applied under voltage clamp. (B) Summary of steady-state, slow inactivation curves
for CAD cells treated with 0.1% DMSO (control) or lacosamide ((R)-1) and affinity bait reagents at concentrations representing 5-fold the
calculated IC50 values for slow inactivation (i.e., 425 μM for (R)-1, 0.5 μM (R)-8, and 1 μM (R)-9). Curves with open symbols represent SI
following a 10 min wash. (C) Representative Boltzmann fits for fast inactivation for CAD cells treated with 0.1% DMSO (control) and various
concentrations of the indicated compounds before and after wash conditions are shown. Data are from 4−8 cells per condition.
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(R)-9 was approximately two times higher than reported for
(R)-6 after cellular wash,7 indicating that (R)-9 was a more
effective affinity bait agent. Additionally, we measured fast
inactivation in these conditions and observed that V1/2 and k
values of (R)-8 or (R)-9 were not significantly different from
those of control-treated cells (Figure 5C).
Next, we asked if the level of Na+ channel slow inactivation is
retained under the experimental test conditions (37 °C) for
extended times, since isothiocyanate covalent adduction has
been shown to be reversible in some cases.45−47 CAD cells were
treated with 1 μM (R)-9 (five times the slow inactivation IC50
value) at 37 °C (10 min), the level of slow inactivation
determined by patch-clamp electrophysiology, the cells washed
(three times, total 10 min), heated at 37 °C an additional 15 or
60 min, washed a second time (three times, total 10 min), and
then the level of slow inactivation measured (Figure 6A). We
observed the extent of slow inactivation (−50 mV) changed
from 19% to 16% after 15 min of incubation (37 °C) and
cellular wash, and to 12% after additional 60 min incubation
and cellular wash (Figure 6B, bars i, ii), indicating that the
modified receptor(s) generated by putative (R)-9 adduction is
likely to be sufficiently stable to permit further characterization
(e.g., receptor site identification). Again, we measured fast
inactivation in these conditions and observed that V1/2 and k
values were not changed by the incubation or wash conditions
employed (Figure 6C).
Extent of (R)-9-Mediated Na+ Channel Slow Inactivation
Increases with (R)-9 Incubation Time. To support the finding
that (R)-9 incubation with CAD cells led to covalent adduction
(Figure 1, 4 → 5) and an increased level of cells in the slow-
inactivated state, we treated CAD cells with 1 μM (five times
the slow inactivation IC50 value) for different time periods (3,
10, 30 min) at 37 °C, determined the fraction of cells in the
presumed slow-inactivated state, then washed the CAD cells
(three times, total: 10 min), and then again determined the
fraction of cells in the slow-inactivated state (Figure 7A). We
expected that those Na+ channels irreversibly converted to the
slow-inactivated state would increase with incubation time
provided sufficient amounts of (R)-9 remained in the cell. We
found that the amount of Na+ channel slow inactivation after
cellular wash progressively increased to 23% over the 30 min
time course (Figure 7B, open bars). Correspondingly, we
observed little change in the extent of fast inactivation over this
time course versus the control (drug untreated) samples after
cellular wash (Figure 7C). Interestingly, the fraction of Na+
channels that transitioned to the slow-inactivated state prior to
cellular wash reached 62% after the first 10 min, but then
diminished to 45% after 30 min (Figure 7B, solid bars). We
have tentatively attributed this trend to the consumption of
(R)-9 by cellular constituents (e.g., glutathione) and the buffer
prior to reacting with the receptor(s) responsible for Na+
channel slow inactivation. If this is the case, the reduced (R)-9
cellular concentration will decrease the levels of Na+ channels
in the slow-inactivated state that result from noncovalent
binding of (R)-9 to the receptor(s) (Figure 1, 4). Collectively,
these results indicate that (R)-9 covalently modifies a
receptor(s) mediating Na+ channel slow inactivation and that
the adduct is sufficiently stable under the test conditions.
■ DISCUSSION
We designed the lacosamide-like affinity bait agents (R)-6, (R)-
8, (R)-9, and (R)-10 to potently inactivate the Na+ channel
slow inactivation process by covalent modification (Figure 1).
Successful adduction requires that the affinity bait agent
efficiently binds to the receptor(s) in close proximity to a
nucleophilic residue on the receptor(s) (Figure 1, 2 + 3 ⇌ 4),
and that the geometry for adduction of the affinity bait by the
nucleophile is correct (Figure 1, 4 → 5). Compounds (R)-6,
(R)-8, and (R)-9 contained an isothiocyanate affinity bait. In
(R)-6, the isothiocyanate moiety was placed in the 4′-position
of the N-benzyl amide moiety. In (R)-8 and (R)-9, the
isothiocyanate group was placed at the 4″ and 3″ positions of
the N-(biphenyl-4′-yl)methyl amide group, respectively.
Finally, in (R)-10, we positioned an acrylamide affinity moiety
at the 3″ position of the N-(biphenyl-4′-yl)methyl amide group.
We found that adding an aryl unit in the N-benzyl amide
moiety of (R)-6 to give (R)-8 and (R)-9 markedly enhanced
Na+ current inhibition (Figure 2). Like the cases of 1 and its 4′-
isothiocyanate derivative 6,7 8-mediated Na+ channel inactiva-
tion preferentially occurred with the (R)-stereoisomer
Figure 6. Effect of the (R)-9 covalent modified adduct on slow
inactivation as a function of time. (A) Experimental design for the
varying incubation and washout conditions. (B) Summary of the
fraction of current available at −50 mV for CAD cells treated with
0.1% DMSO (control) or 1 μM (R)-9 without and with wash and
varying incubations (as indicated in (A)). Asterisk (∗) indicates
statistically significant differences in fraction of current available
between the 1 μM (R)-9 condition and following washout of 1 μM
(R)-9 (p < 0.05, one-way ANOVA with Dunnett’s posthoc test). (C)
Representative Boltzmann fits for fast inactivation for CAD cells
treated with 0.1% DMSO (control) and various concentrations of the
indicated compounds before and after wash conditions are shown.
Numbers in parentheses are the number of cells patched per condition.
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compared with the (S)-isomer (Figures 2 and 4). We further
demonstrated that (R)-8 and (R)-9, like (R)-1, preferentially
increased Na+ channel slow inactivation but not fast
inactivation processes (Figure 4, Table 2). Addition of the
aryl unit to (R)-6 to give (R)-8 led to an ∼80-fold increase in
Na+ channel slow inactivation activity. Similarly, we observed
an ∼40-fold increase in slow inactivation activity in going from
(R)-6 to (R)-9 (IC50 (μM): (R)-6, 8.1;
7 (R)-8, 0.1; (R)-9, 0.2).
The decreases in the IC50 values for (R)-8 and (R)-9 compared
with (R)-6 are similar to the decrease reported in proceeding
from (R)-1 to (R)-7 (IC50 (μM): (R)-1, 85;
7 (R)-7, 2.934).
Substitution of the 3″-isothiocyanate moiety in (R)-9 by the 3″-
acrylamide unit to give (R)-10 led to a sharp increase in the
IC50 value for Na
+ channel slow inactivation, suggesting that the
increase in steric size that accompanies this structural change
affected binding (IC50 (μM): (R)-9, 0.2; (R)-10, 401.0) (Figure
4). Additional studies will be needed to confirm if the size of
the 3″-substituent affects binding (Figure 1, 2 + 3 ⇌ 4).
Together, these findings indicated that aryl extension of the
(R)-1 framework, in select cases, did not principally alter the
mode of function of these agents but did increase their ability to
modulate the Na+ channel slow inactivation process.
Compounds (R)-8 and (R)-9 were designed to act as affinity
bait reagents, wherein the isothiocyanate group was incorpo-
rated to react with a nearby nucleophilic residue on the
receptor(s) upon compound binding. Since isothiocyanate-
based affinity baits have been shown, in some cases, to undergo
reversible covalent modification,47−49 we tested whether the
CAD cell Na+ channels remained in the slow inactivation state
after (R)-8 or (R)-9 treatment and cellular wash, and whether
slow inactivation was observed upon further heating. We found
that using concentrations that were five times the affinity bait
agents’ IC50 value, that (R)-9, but not (R)-8, led to increased
levels of slow inactivation after cellular wash (Figure 5), and
that with further heating the level of slow inactivation for the
treated (R)-9 CAD cells remained nearly constant for the first
15 min and then modestly decreased after 60 min of heating
(Figure 6B). To further support the notion that the incubation
of CAD cells with (R)-9 led to the covalent modification of a
receptor(s) responsible for slow inactivation, we showed that
lengthening the incubation times from 3 to 30 min increased
the level of Na+ channel slow inactivation after cellular wash
(Figure 7B). The nonreversible modification of Na+ channels
by (R)-9 could have two functional effects on channel kinetics:
(R)-9-bound channels remain closed or (R)-9-bound channels
promote an inactive state, but the channels are still able to cycle
through closed, open, and inactive states. In the first case,
bound channels should have no contribution to available
current and, consequently, there should be no shift in the slow
inactivation availability curve following a channel inactivating
protocol. Our data (Figure 5B) shows that, following
incubation with (R)-9 and subsequent washout, a 5 s
inactivating pulse reduces the available current compared to
control. These results support the second scenario, in which
(R)-9-bound Na+ channels are available to contribute current in
response to depolarized conditioning pulses that promote
resting, closed state. In the case of depolarized conditioning
pulses that promote inactivation, the available current is
reduced, suggesting that (R)-9-bound channels have enhanced
transition into, or inhibit exit from, an inactivated conforma-
tion.
The findings that Na+ channel slow inactivation but not fast
inactivation properties in CAD cells were likely affected with
(R)-9 treatment (Figure 4, Table 2) and that these effects
remained after cellular wash are important (Figure 5). Previous
studies have shown that reversible agents, such as (R)-1,
affected only slow inactivation.5−7 Our findings now show that
(R)-9 can retain a fraction of the channels in a slow inactivated
state refractory to washout. Moreover, our findings support
previous projections that fast and slow inactivation are
uncoupled.50
■ CONCLUSIONS
We have discovered a promising structural template to
investigate the voltage-gated Na+ channel slow inactivation
process. The molecular pathway (or pathways) that promote
slow inactivation are poorly understood and several domains in
the Na+ channel have been implicated in the conformational
change needed to affect current flow.46,51,52 We anticipate that
Figure 7. Effect of reaction times on (R)-9 mediated steady-state slow
inactivation state of Na+ currents in CAD cells. (A) Experimental
design for the varying incubation and washout conditions. (B)
Summary of the fraction of current available at −50 mV for CAD cells
treated with 0.1% DMSO (control) or treated with 1 μM (R)-9 for 3,
10, and 30 min (closed bars) and following washout of each of these
conditions (open bars). Asterisks (∗) indicate statistically significant
differences in fraction of current available between the 1 μM (R)-9
condition and following its corresponding washout condition or
compared to control at the 10 min incubation time (p < 0.05, one-way
ANOVA with Dunnett’s posthoc test). (C) Representative Boltzmann
fits for fast inactivation for CAD cells treated with 0.1% DMSO
(control) and various concentrations of the indicated compounds
before and after wash conditions are shown. Data are from 4−7 cells
per condition.
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(R)-9 or similar agents may prove useful to identify the
receptor(s) and the structural site on the receptor responsible
for Na+ channel slow inactivation. This information is expected
to be useful in future drug design efforts.
■ METHODS
Chemistry. (4″-N-(tert-Butoxycarbonyl)aminobiphenyl-4′-yl)-
methylamine (14). To a dry CH3CN solution (15 mL) of p-
bromobenzylamine (11) (0.78 g, 4.2 mM) was added 4-(N-tert-
butoxycarbonylamino)phenylboronic acid (12) (1.00 g, 4.2 mM).
Then, a solution of 1 N K2CO3 (15 mL) was added and the mixture
was stirred and heated at reflux under Ar. After 15 min, tetrakis-
(triphenylphosphine)palladium(0) (0.19 g, 0.2 mM) was added and
stirred at 90 °C (12−16 h). The mixture was filtered and evaporated in
vacuo. The resulting residue was dissolved in EtOAc (100 mL) and
washed with H2O (100 mL) and brine (100 mL). The organic layer
was dried (Na2SO4). Concentrated aqueous HCl (0.1 mL) was added
to the organic layer and stirred at room temperature (1 h), and the
precipitate filtered and washed with hexanes to obtain (4″-N-(tert-
butoxycarbonyl)aminobiphenyl-4′-yl)methylamine hydrochloride as a
yellow solid (0.88 g, 62%): Rf = 0.00 (hexanes/EtOAc 1/2); mp 242−
244 °C; 1H NMR (DMSO-d6) δ 1.49 (s, C(CH3)3), 4.03−4.04 (br m,
CH2), 7.56−7.68 (m, 8 ArH), 8.59 (s, NH3Cl), 9.47 (s, NH); 13C
NMR (DMSO-d6) δ 28.1 (C(CH3)3), 41.8 (CH2), 79.1 (C(CH3)3),
118.4, 126.1, 126.8, 129.5, 132.6, 133.0, 139.3, 139.8 (ArC), 155.2
(NC(O)O); HRMS (ESI+) 321.1630 [M − HCl + Na]+ (calcd for
C18H22N2O2Na
+ 321.1620).
The resulting solid was added to a NaOH solution (pH 10, 100
mL), and then the aqueous layer extracted with CH2Cl2 (3 × 100 mL).
The organic layers were combined, dried (Na2SO4), and concentrated
in vacuo. The resulting residue (0.72 g, 92%) was used without further
purification.
(R)-N-(4″-N-(tert-Butoxycarbonyl)aminobiphenyl-4′-yl)methyl 2-
Acetamido-3-methoxypropionamide ((R)-17). To a cooled THF
solution (−78 °C, dry ice acetone bath) of (R)-1629 (0.18 g, 1.1
mmol) were successively added N-methylmorpholine (NMM) (0.18
mL, 1.6 mmol), stirred for 2 min, isobutylchloroformate (IBCF) (0.18
mL, 1.4 mmol), stirred for 5 min, and then 14 (0.39 g, 1.3 mmol).
Upon addition, the reaction mixture was allowed to warm to room
temperature and further stirred (2−3 h). The salts were filtered and
rinsed with THF, and the filtrate was concentrated in vacuo. The
residue obtained was purified by column chromatography on SiO2 to
give (R)-17 as a white solid (0.34 g, 70%): Rf = 0.45 (MeOH/CHCl3
1/15); mp 187−188 °C; [α]26D −12.7° (c 1.1, CHCl3); 1H NMR
(CDCl3) δ 1.53 (s, C(CH3)3), 2.04 (s, C(O)CH3), 3.40 (s, OCH3),
3.45 (dd, J = 7.6, 9.2 Hz, CHH′OCH3), 3.82 (dd, J = 4.0, 9.2 Hz,
CHH′OCH3), 4.45−4.58 (m, CH2N, CH), 6.44 (d, J = 6.4 Hz,
NHCH), 6.55 (s, NH-tBoc), 6.76−6.79 (br t, NHCH2), 7.23 (d, J =
8.6 Hz, 2 ArH), 7.42 (d, J = 8.6 Hz, 2 ArH), 7.49−7.53 (m, 4 ArH);
13C NMR (DMSO-d6) δ 22.5 (C(O)CH3), 28.1 (C(CH3)3), 41.7
(NCH2), 52.6 (OCH3), 58.2 (OCH2CH), 72.1 (OCH2CH), 79.1
(C(CH3)3), 118.4, 125.9, 126.7, 127.5, 133.5, 137.9, 138.2, 138.9
(ArC), 152.7 (NC(O)O), 169.5, 169.8 (2 C(O)); HRMS (ESI+)
574.1320 [M + Cs]+ (calcd for C24H31N3O5Cs
+ 574.1318).
(S)-N-(4″-N-(tert-Butoxycarbonyl)aminobiphenyl-4′-yl)methyl 2-
Acetamido-3-methoxypropionamide ((S)-17). Utilizing the preced-
ing procedure and using (S)-16 (0.13 g, 0.8 mmol), NMM (0.14 mL,
1.2 mmol), IBCF (0.14 mL, 1.0 mmol), and 14 (0.30 g, 1.0 mmol)
gave (S)-17 (0.24 g, 65%) as a white solid: Rf = 0.45 (MeOH/CHCl3
1/15); mp 186−188 °C; [α]26D +12.9° (c 1.0, CHCl3); 1H NMR
(DMSO-d6) δ 1.49 (s, C(CH3)3), 1.88 (s, C(O)CH3), 3.27 (s,
OCH3), 3.48−3.55 (m, CH2OCH3), 4.31 (d, J = 6.0 Hz, CH2N),
4.47−4.52 (m, CH), 7.29 (d, J = 8.0 Hz, 2 ArH), 7.52−7.57 (m, 6
ArH), 8.08 (d, J = 8.0 Hz, NHCH), 8.49 (t, J = 6.0 Hz, NHCH2), 9.41
(s, NH-tBoc); 13C NMR (DMSO-d6) δ 22.5 (C(O)CH3), 28.2
(C(CH3)3), 41.7 (NCH2), 52.5 (OCH3), 58.2 (OCH2CH), 72.1
(OCH2CH), 79.1 (C(CH3)3), 118.3, 125.9, 126.7, 127.5, 133.5, 137.9,
138.2, 138.9 (ArC), 152.8 (NC(O)O), 169.5, 169.8 (2 C(O)); HRMS
(ESI+) 574.1268 [M + Cs]+ (calcd for C24H31N3O5Cs
+ 574.1318).
(R)-N-(4″-Isothiocyanatobiphenyl-4′-yl)methyl 2-Acetamido-3-
methoxypropionamide ((R)-8). (R)-17 (0.26 g, 0.6 mmol) was
dissolved in CH2Cl2 (5 mL) and treated with 4 M HCl in dioxane (0.7
mL) at room temperature (4 h). The resulting precipitate was filtered
and washed with hexanes. The resulting solid was added to a NaOH
solution (pH 10, 50 mL), and then the aqueous layer extracted with
CH2Cl2 (3 × 50 mL). The organic layers were combined, dried
(Na2SO4), and concentrated in vacuo. The resulting residue was
dissolved in THF (10 mL) and treated with di(2-pyridyl)
thionocarbonate (DPT) (0.24 mg, 1.0 mmol) at room temperature
(16 h). The solvent was removed in vacuo, and the product was
purified by silica gel column chromatography (1/9 acetone/EtOAc) to
give 0.17 g (75%) of (R)-8 as a white solid: Rf = 0.45 (acetone/EtOAc
1/9); mp 225−226 °C; [α]26D −20.2° (c 0.3, CHCl3); IR (nujol)
3280, 2924, 2859, 2084, 1633, 1547, 1458, 1374, 1109, 926, 811 cm−1;
1H NMR (DMSO-d6) δ 1.88 (s, C(O)CH3), 3.27 (s, OCH3), 3.48−
3.56 (m, CH2OCH3), 4.33 (d, J = 6.0 Hz, CH2N), 4.48−4.53 (m,
CH), 7.35 (d, J = 8.0 Hz, 2 ArH), 7.51 (d, J = 7.8 Hz, 2 ArH), 7.64 (d,
J = 8.0 Hz, 2 ArH), 7.74 (d, J = 7.8 Hz, 2 ArH), 8.10 (d, J = 7.6 Hz,
NHCH), 8.52 (t, J = 6.0 Hz, NHCH2), addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-8 gave only one signal
for the acetyl methyl and one signal for the ether methyl protons; 13C
NMR (DMSO-d6) δ 22.5 (C(O)CH3), 41.7 (NCH2), 52.6 (OCH3),
58.2 (OCH2CH), 72.1 (OCH2CH), 126.4, 126.5, 127.7, 127.8, 129.0
(ArC), 133.6 (NCS), 137.0, 139.2, 139.3 (ArC), 169.4, 169.8 (2
C(O)); LRMS (ESI+) 406.1 [M + Na]+ (calcd for C20H21N3O3SNa
+
406.1); Anal. Calcd. for C20H21N3O3S: C, 62.64; H, 5.52; N, 10.96; S,
8.36. Found: C, 62.48; H, 5.46; N, 10.80; S, 8.17.
(S)-N-(4″-Isothiocyanatobiphenyl-4′-yl)methyl 2-Acetamido-3-
methoxypropionamide ((S)-8). Utilizing the preceding procedure
and using (S)-17 (0.15 g, 0.3 mmol), 4 M HCl in dioxane (0.4 mL),
and DPT (0.22 mg, 0.2 mmol) gave 0.09 g (69%) of (S)-8 as a white
solid: Rf = 0.45 (acetone/EtOAc 1/9); mp 224−226 °C; [α]26D +20.7°
(c 0.3, CHCl3); IR (nujol) 3282, 2924, 2858, 2084, 1636, 1547, 1458,
1374, 1107, 922, 812, 727 cm−1; 1H NMR (DMSO-d6) δ 1.88 (s,
C(O)CH3), 3.27 (s, OCH3), 3.47−3.56 (m, CH2OCH3), 4.33 (d, J =
6.0 Hz, CH2N), 4.47−4.52 (m, CH), 7.34 (d, J = 8.0 Hz, 2 ArH), 7.51
(d, J = 8.4 Hz, 2 ArH), 7.64 (d, J = 8.0 Hz, 2 ArH), 7.74 (d, J = 8.4 Hz,
2 ArH), 8.09 (d, J = 8.0 Hz, NHCH), 8.51 (t, J = 6.0 Hz, NHCH2),
addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (S)-8
gave only one signal for the acetyl methyl and one signal for the ether
methyl protons; 13C NMR (DMSO-d6) δ 22.6 (C(O)CH3), 41.7
(NCH2), 52.7 (OCH3), 58.2 (OCH2CH), 72.1 (OCH2CH), 126.4,
126.5, 127.7, 127.8, 129.0 (ArC), 133.6 (NCS), 137.0, 139.2, 139.4




drochloride. Employing the procedure described for 14 and using 11
(0.78 g, 4.2 mmol), acetonitrile (15 mL), 13 (1.00 g, 4.2 mmol),
tetrakis(triphenylphosphine)palladium(0) (0.19 g 0.2 mmol), and
aqueous 1 N K2CO3 (15 mL) gave the desired product (0.25 g, 35%)
as a yellow solid: Rf = 0.00 (hexanes/EtOAc 1/1); mp 192−195 °C;
1H NMR (CD3OD) δ 1.53 (s, C(CH3)3), 4.14−4.18 (br s, CH2N),
7.21−7.76 (m, 8 ArH); 13C NMR (DMSO-d6) δ 28.6 (C(CH3)3), 42.3
(CH2NH3), 79.6 (C(CH3)3), 120.9, 127.1, 129.7, 130.0, 131.6, 131.8,
133.9, 140.5, 140.6, 140.8, (10 ArC), 153.3 (HNC(O)); LRMS (ES+)
299.18 [M − Cl]+ (calcd for C18H23N2O2+ 299.18); HRMS (ESI+)
299.1755 [M − Cl]+ (calcd for C18H23N2O2+ 299.1754).
(R)-N-(3″-tert-Butoxycarbonylaminobiphenyl-4′-yl)methyl 2-
Acetamido-3-methoxypropionamide ((R)-18). To an aqueous
NaOH solution (pH = 10.0, 50 mL) was added the (3′-tert-
butoxycarbonylaminobiphenyl-4-yl)methylamine hydrochloride (0.54
g, 1.6 mmol) and extracted with CH2Cl2 (3 × 50 mL). The organic
layers were combined, dried (Na2SO4), and concentrated in vacuo.
The resulting residue was further dried under high vacuum (16 h) to
give the desired product (3′-tert-butoxycarbonylaminobiphenyl-4-
yl)methylamine (15). The amine was immediately used without
further purification.
Employing the procedure described for (R)-8 and using (R)-16
(0.26 g, 1.6 mmol), NMM (0.24 g, 2.4 mmol), IBCF (0.33 g, 2.4
ACS Chemical Neuroscience Research Article
dx.doi.org/10.1021/cn300188h | ACS Chem. Neurosci. 2013, 4, 463−474471
mmol), and 15 gave the desired product (R)-18 (405 mg, 57%) as a
white solid: Rf = 0.36 (EtOAc/hexanes 1/1); mp 189−192 °C; [α]25D
−12.9° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 1.53 (s, C(CH3)3), 2.02
(s, CH3C(O)), 3.38 (s, OCH3), 3.43−3.47 (m, CHH′OCH3), 3.77−
3.84 (m, CHH′OCH3), 4.45−4.51 (d, J = 6.0 Hz, CH2N), 4.55−4.61
(m, CH), 6.50−6.58 (br d, NHCH), 6.66 (s, NHC(O)O), 6.85−6.96
(br t, NHCH2), 7.20−7.36 (m, 5 ArH), 7.53 (d, J = 8.0 Hz, 2 ArH),
7.62 (s, ArH), addition of excess (R)-(−)-mandelic acid to a CDCl3
solution of the product gave only one signal for the acetyl methyl and
one signal for the ether methyl protons; 13C NMR (CDCl3) δ 23.3
(CH3C(O)), 28.4 (C(CH3)3), 43.3 (NCH2), 52.5 (CH), 59.2
(OCH3), 71.8 (OCH2), 80.7 (C(CH3)3), 117.3, 117.6, 121.8, 127.5,
127.9, 129.4, 137.1, 138.9, 140.2, 141.6 (10 ArC), 152.9 (OC(O)NH),
170.1, 170.4 (C(O)); LRMS (ES+) 442.19 [M + H]+ (calcd for
C24H32N3O5




propionamide ((R)-20). To a solution of (R)-18 (0.26 g, 0.59
mmol) in CH2Cl2 (5 mL) was added 4 M HCl in dioxane (0.7 mL)
and stirred at room temperature (4 h). The reaction mixture was
filtered and washed with hexanes. The resulting solid was added to an
aqueous NaOH solution (pH 10, 50 mL) and the resulting mixture
was extracted with CH2Cl2 (3 × 50 mL). The organic layers were
combined, dried (Na2SO4), and concentrated in vacuo to give the
desired product (R)-20 (0.20 g, 100%) as a white solid: Rf = 0.21
(EtOAc); mp 99−100 °C; [α]23.5D +2.6 ° (c 0.25, CHCl3); 1H NMR
(CDCl3) δ 1.99 (s, C(O)CH3), 3.36 (s, OCH3), 3.45−3.56 (dd, J =
4.0, 9.2 Hz, CHH′OCH3), 3.76−3.80 (dd, J = 7.2, 9.2 Hz,
CHH′OCH3), 4.41−4.46 (dd, J = 5.8, 15.0 Hz, CHH′N), 4.46−
4.51 (dd, J = 5.8, 15.0 Hz, CHH′N), 4.59−4.64 (m, CH), 6.63−6.67
(m, NHCH, 1 ArH), 6.85 (m, 1 ArH), 6.93−6.96 (m, 1 ArH), 6.99−
7.05 (br t, NHCH2), 7.20 (t, J = 7.8 Hz, 1 ArH), 7.26 (d, J = 6.0 Hz, 2
ArH), 7.49 (dd, J = 1.6, 6.4 Hz, 2 ArH); 13C NMR (CDCl3/CD3OD)
δ 22.6 (C(O)CH3), 43.2 (NCH2), 53.0 (CH), 59.1 (OCH3), 72.1
(OCH2CH), 118.8, 123.0, 127.3, 127.4, 129.3, 137.1, 138.8, 140.0,
141.5 (9 ArC), 170.4, 171.6 (2 C(O)), one aromatic resonance was
not detected and is believed to overlap with nearby signals; LRMS
(ES+) 342.22 [M + H]+ (calcd for C19H24N3O3
+ 342.17); HRMS
(ESI+) 342.1820 [M + H]+ (calcd for C19H24N3O3
+ 342.1739).
(R)-N-(3″-Isothiocyanatobiphenyl-4′-yl)methyl 2-Acetamido-3-
methoxypropionamide ((R)-9). To a solution of (R)-20 (70 mg,
0.20 mmol) in dry THF (6 mL) was added DPT (96 mg, 0.41 mmol)
and stirred at room temperature (16 h). The reaction mixture was
concentrated in vacuo. The resulting residue was purified by silica gel
column chromatography (acetone/EtOAc 1/9) to give the desired
product (R)-9 (0.17 g, 64%) as a white solid: Rf = 0.32 (EtOAc); mp
176−177 °C; [α]23.5D +1.0° (c 1.0, CHCl3); 1H NMR (CDCl3) δ 2.02
(s, C(O)CH3), 3.39 (s, OCH3), 3.48 (dd, J = 7.2, 9.2 Hz,
CHH′OCH3), 3.81 (dd, J = 4.4, 9.2 Hz, CHH′OCH3), 4.48−4.51
(m, CH2N), 4.58−4.63 (m, CH), 6.59 (d, J = 6.8 Hz, NHCH), 7.03 (t,
J = 5.4 Hz, NHCH2), 7.18−7.20 (m, 1 ArH), 7.32−7.50 (m, 7 ArH),
addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of the
product gave only one signal for the acetyl methyl and one signal for
the ether methyl protons; 13C NMR (CDCl3) δ 23.3 (C(O)CH3),
43.3 (NCH2), 52.8 (CH), 59.3 (OCH3), 72.1 (OCH2CH), 124.4,
124.6, 126.1, 127.5, 128.2, 130.2, 132.0 (7 ArC), 135.9 (NCS), 138.1,
138.8, 142.6 (3 ArC), 170.4, 170.7 (2 C(O)); LRMS (ES+) 383.14 [M
+ H]+ (calcd for C20H21N3O3S
+ 383.13); HRMS (ESI+) 406.1199 [M
+ Na]+ (calcd for C20H21N3O3SNa
+ 406.1201).
(R)-N-(3″-Acrylamidobiphenyl-4′-yl)methyl 2-Acetamido-3-me-
thoxypropionamide ((R)-10). To a solution of (R)-20 (100 mg,
0.29 mmol) in dry THF (6 mL) was added triethylamine (Et3N) (45
mg 0.44 mmol) and acryloyl chloride (40 mg, 0.44 mmol) and stirred
at room temperature (16 h). The reaction mixture was concentrated in
vacuo. The resulting residue was purified by silica gel column
chromatography (EtOAc) to give the desired product (R)-10 (68 mg,
60%) as a white solid: Rf = 0.21 (CH2Cl2/MeOH 95/5); mp 183−184
°C; [α]23.5D +8.6°(c 0.1, CHCl3/MeOH 95/5);
1H NMR (CDCl3/
CD3OD) δ 2.03 (s, C(O)CH3), 3.37 (s, OCH3), 3.52−3.56 (dd, J =
5.6, 9.6 Hz, CHH′OCH3), 3.72 (dd, J = 4.6, 9.6 Hz, CHH′OCH3),
4.40−4.50 (br s, CH2N), 4.59 (dd, J = 4.6, 5.6 Hz, CH), 5.75 (dd, J =
2.4, 9.2 Hz, C(O)CHCH2), 6.33−6.45 (m, C(O)CHCH2), 7.30 (d, J
= 8.0 Hz, 3 ArH), 7.37 (t, J = 7.8 Hz, 1 ArH), 7.54 (d, J = 8.4 Hz, 2
ArH), 7.60 (d, J = 7.6 Hz, 1 ArH), 7.87 (s, 1 ArH), addition of excess
(R)-(−)-mandelic acid to a CDCl3/CD3OD solution of the product
gave only one signal for the acetyl methyl and one signal for the ether
methyl protons; 13C NMR (CDCl3/CD3OD) δ 22.6 (C(O)CH3),
43.1 (NCH2), 53.1 (CH), 59.0 (OCH3), 72.1 (OCH2CH), 118.8,
123.0, 127.3, 127.4 (4 ArC), 127.8 (C(O)CHCH2), 129.3 (ArC),
131.3 (C(O)CHCH2), 137.1, 138.8, 140.0, 141.5 (4 ArC), 164.9,
170.5, 171.7 (3 C(O)), one downfield resonance was not detected and
is believed to overlap with nearby signals; LRMS (ES+) 418.25 [M +
Na]+ (calcd for C22H25N3O4Na
+ 418.17); HRMS (ESI+) 418.1736 [M
+ Na]+ (calcd for C22H25N3O4Na
+ 418.1743).
Catecholamine A Differentiated (CAD) Cells. CAD cells were
grown at 37 °C and in 5% CO2 (Sarstedt, Newton, NC) in Ham’s
F12/EMEM medium (GIBCO, Grand Island, NY), supplemented
with 8% fetal bovine serum (FBS; Sigma, St. Louis, MO) and 1%
penicillin/streptomycin (100% stocks, 10 000 U/mL penicillin G
sodium and 10 000 μg/mL streptomycin sulfate).7,34,39,40 Cells were
passaged every 6−7 days at a 1:25 dilution. We typically observe
variations in peak Na+ current density, but not Na+ channel isoform
type (data not shown), over passages. Therefore, to minimize variation
in current expression, all experiments for this paper were conducted
with cells of a similar passage number.
Electrophysiology. Whole-cell voltage-clamp recordings were
performed at room temperature on CAD cells using an EPC 10
amplifier (HEKA Electronics, Germany). Electrodes were pulled from
thin-walled borosilicate glass capillaries (Warner Instruments,
Hamden, CT) with a P-97 electrode puller (Sutter Instrument,
Novato, CA) such that final electrode resistances were 1−2 MΩ when
filled with internal solutions. The internal solution for recording Na+
currents contained (in mM): 110 CsCl, 5 MgSO4, 10 EGTA, 4 ATP
Na2-ATP, 25 Hepes (pH 7.2, 290−310 mOsm/L). The external
solution contained (in mM) 100 NaCl, 10 tetraethylammonium
chloride (TEA-Cl), 1 CaCl2, 1 CdCl2, 1 MgCl2, 10 D-glucose, 4 4-AP,
0.1 NiCl2, 10 Hepes (pH 7.3, 310−315 mOsm/L). Whole-cell
capacitance and series resistance were compensated with the amplifier.
Series resistance errors were compensated to be less than 3 mV by
using 40−75% series resistance compensation and 1.0- to 2.0-MΩ
pipettes. Linear leak currents were digitally subtracted by P/4. To
negate any potential effects of time-dependent shifts in the voltage
dependence of fast inactivation, we compared data obtained 3−4 min
after establishing the whole-cell recording configuration from cells
without drug against separate cells with the lacosamide derivatives.
Conditions for Incubation of Affinity Based Agents and
Washes. These experiments were conducted on separate sets of cells
in parallel. For experiments designed to determine if lacosamide
derivatives interacted in a reversible or irreversible manner to affect
slow inactivation, the agents (details of concentrations provided in the
figure legends) were applied to the CAD cells for 10 min at 37 °C,
then washed three times for a total of 10 min at 37 °C prior to whole-
cell electrophysiology. The agents were not applied under voltage
clamp. The washes (2 mL each) were performed using complete
Ham’s F12/EMEM medium. Cells were incubated at 37 °C during the
washes. Following this washing regimen, the cells were placed in 0.5
mL of extracellular bathing solution for up to 3 min prior to
establishing recording seals.
Data Acquisition and Analysis. Signals were filtered at 10 kHz
and digitized at 10−20 kHz. Analysis was performed using Fitmaster
and Origin8.1 (OriginLab Corporation, Northampton, MA). For
activation curves, conductance (G) through Na+ channels was
calculated using the equation G = I/(Vm − Vrev), where Vrev is the
reversal potential, Vm is the membrane potential at which the current
was recorded, and I is the peak current. Activation and inactivation
curves were fitted to a single-phase Boltzmann function G/Gmax = 1/{1
+ exp[(V − V50)/k]}, where G is the peak conductance, Gmax is the
fitted maximal G, V50 is the half activation voltage, and k is the slope
factor. Additional details of specific pulse protocols are described in
the Results text or figure legends.
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Statistical Analyses. Differences between means were compared
by either paired or unpaired, two-tailed Student’s t-tests or an analysis
of variance (ANOVA), when comparing multiple groups (repeated
measures whenever possible). If a significant difference is determined
by ANOVA, then a Dunnett’s or Tukey’s posthoc test was performed.
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■ ABBREVIATIONS
AED, antiepileptic drug; VGSC, voltage-gated Na+ channel;
MES, maximal electroshock; CAD, catecholamine A differ-
entiated; DPT, di(2-pyridyl) thionocarbonate; IBCF, isobutyl-
chloroformate; Nav1.x, voltage-gated Na
+ channel isoform 1.x;
INa, Na
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